Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALUR Stock Forecast 2026-2027
$0.72
Current Price
$12.00M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ALUR Price Targets
+1,011.1%
To High Target of $8.00
+663.9%
To Median Target of $5.50
+316.7%
To Low Target of $3.00
ALUR Price Momentum
-18.2%
1 Week Change
+140.0%
1 Month Change
-69.5%
1 Year Change
-41.5%
Year-to-Date Change
-78.9%
From 52W High of $3.42
+213.0%
From 52W Low of $0.23
📊 TOP ANALYST CALLS
Did ALUR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Allurion is one of their latest high-conviction picks.
Latest ALUR Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ALUR has a bullish consensus with a median price target of $5.50 (ranging from $3.00 to $8.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.72, the median forecast implies a 663.9% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 316.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALUR Analyst Ratings
2
Buy
0
Hold
0
Sell
ALUR Price Target Range
Low
$3.00
Average
$5.50
High
$8.00
Current: $0.72
Latest ALUR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALUR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | Chardan Capital | Keay Nakae | Buy | Upgrade | $3.00 |
| Nov 20, 2025 | Chardan Capital | Keay Nakae | Neutral | Maintains | $2.50 |
| Mar 27, 2025 | Chardan Capital | Keay Nakae | Neutral | Maintains | $2.50 |
| Mar 21, 2025 | Chardan Capital | Keay Nakae | Neutral | Maintains | $2.50 |
| Mar 21, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $16.00 |
| Nov 14, 2024 | Chardan Capital | Keay Nakae | Neutral | Downgrade | $N/A |
| Oct 2, 2024 | TD Cowen | Joshua Jennings | Buy | Initiates | $2.00 |
| Sep 6, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $2.00 |
| Aug 22, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.50 |
| May 15, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| Apr 4, 2024 | Chardan Capital | Keay Nakae | Buy | Initiates | $5.00 |
| Feb 9, 2024 | Jefferies | Matthew Taylor | Buy | Initiates | $5.00 |
Allurion Technologies Inc. (ALUR) Competitors
The following stocks are similar to Allurion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Allurion Technologies Inc. (ALUR) Financial Data
Allurion Technologies Inc. has a market capitalization of $12.00M with a P/E ratio of 32.9x. The company generates $15.23M in trailing twelve-month revenue with a -188.8% profit margin.
Revenue growth is -35.4% quarter-over-quarter, while maintaining an operating margin of -174.2% and return on equity of +37.3%.
Valuation Metrics
Market Cap
$12.00M
Enterprise Value
$82.76M
P/E Ratio
32.9x
PEG Ratio
-0.6x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
-35.4%
Gross Margin
+44.5%
Operating Margin
-174.2%
Net Margin
-188.8%
EPS Growth
-35.4%
Financial Health
Cash/Price Ratio
+50.1%
Current Ratio
0.3x
Debt/Equity
-1.0x
ROE
+37.3%
ROA
-77.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Allurion Technologies Inc. (ALUR) Business Model
About Allurion Technologies Inc.
What They Do
Develops non-invasive weight loss medical devices.
Business Model
Allurion Technologies generates revenue by offering innovative medical devices, particularly the Elipse Balloon, which aids weight loss without surgery. The company operates in the healthcare sector, targeting hospitals, clinics, and wellness centers to reach patients seeking effective weight management solutions.
Additional Information
With the rising global obesity rates, Allurion's non-surgical approach addresses a critical health issue while also aiming to lower healthcare costs. The company's commitment to integrating digital tools into its offerings enhances patient support and monitoring, reinforcing its competitive edge in the medical technology and wellness markets.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
134
CEO
Dr. Shantanu K. Gaur M.D.
Country
United States
IPO Year
2023
Website
www.allurion.comAllurion Technologies Inc. (ALUR) Latest News & Analysis
Latest News
Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy
29 days ago
Quick Summary
Allurion Technologies (OTCID: ALUR) has started training partner accounts in the U.S. and manufacturing FDA-approved products, with shipping expected to begin in April, marking key commercial expansion.
Why It Matters
Allurion Technologies' onboarding of partner accounts and FDA-approved product manufacturing signals a significant expansion, potentially boosting revenue and market presence, which can positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Allurion Technologies, Inc. (OTCID: ALUR) has appealed the NYSE's decision to initiate delisting proceedings due to failure to maintain required market capitalization levels.
Why It Matters
Allurion Technologies' appeal against NYSE delisting highlights its market position and potential financial instability, affecting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The NYSE is initiating delisting proceedings for Allurion Technologies, Inc. due to the company falling below listing requirements, as per Section 802.01B of its manual.
Why It Matters
Delisting from the NYSE signals financial instability and can erode investor confidence, leading to lower stock prices and diminished liquidity for Allurion Technologies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Allurion Technologies, Inc. (NYSE: ALUR) may face delisting from the NYSE due to non-compliance with stockholders' equity requirements, as it failed to meet the $50 million threshold.
Why It Matters
Allurion Technologies faces potential delisting from the NYSE due to insufficient stockholders' equity, which could significantly impact its stock price and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Allurion Technologies, Inc. (ALUR) and McKesson (MCK) have been evaluated against their sector's performance for the year to date. Further details on performance metrics were not provided.
Why It Matters
Performance comparisons indicate how well ALUR and MCK are faring relative to their sector, impacting investor sentiment and potential investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced a definitive agreement for the immediate exercise of warrants for 2,659,565 shares of common stock, expiring in 2025.
Why It Matters
The exercise of warrants can increase stock supply, potentially diluting existing shares. This may impact share price and investor sentiment regarding Allurion's financial health.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ALUR Stock
What is Allurion Technologies Inc.'s (ALUR) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Allurion Technologies Inc. (ALUR) has a median price target of $5.50. The highest price target is $8.00 and the lowest is $3.00.
Is ALUR stock a good investment in 2026?
According to current analyst ratings, ALUR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALUR stock?
Wall Street analysts predict ALUR stock could reach $5.50 in the next 12 months. This represents a 663.9% increase from the current price of $0.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Allurion Technologies Inc.'s business model?
Allurion Technologies generates revenue by offering innovative medical devices, particularly the Elipse Balloon, which aids weight loss without surgery. The company operates in the healthcare sector, targeting hospitals, clinics, and wellness centers to reach patients seeking effective weight management solutions.
What is the highest forecasted price for ALUR Allurion Technologies Inc.?
The highest price target for ALUR is $8.00 from at , which represents a 1,011.1% increase from the current price of $0.72.
What is the lowest forecasted price for ALUR Allurion Technologies Inc.?
The lowest price target for ALUR is $3.00 from Keay Nakae at Chardan Capital, which represents a 316.7% increase from the current price of $0.72.
What is the overall ALUR consensus from analysts for Allurion Technologies Inc.?
The overall analyst consensus for ALUR is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.50.
How accurate are ALUR stock price projections?
Stock price projections, including those for Allurion Technologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 3:33 AM UTC